138647-50-4

Basic information

• Product Name: 1(2H)-Pyridinecarboxylic acid, 4-(4-chlorophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester
• Synonyms: tert-butyl-4-(4-chlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate;tert-butyl 4-(4-chlorophenyl)-1,2,3,6-tetrahydro-pyridine-1-carboxylate;tert-butyl 4-(4-chlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate;4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester;4-(4-chlorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 138647-50-4
• Molecular Formula: C16H20ClNO2
• Molecular Weight: 293.793
• Mol File: 138647-50-4.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: 1(2H)-Pyridinecarboxylic acid, 4-(4-chlorophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1(2H)-Pyridinecarboxylic acid, 4-(4-chlorophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester(138647-50-4)
• EPA Substance Registry System: 1(2H)-Pyridinecarboxylic acid, 4-(4-chlorophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester(138647-50-4)

Safety Data

• Hazardous Substances Data: 138647-50-4(Hazardous Substances Data)

Usage

General Description

1(2H)-Pyridinecarboxylic acid, 4-(4-chlorophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester is a chemical compound with the molecular formula C18H20ClNO2. It is commonly known as Clonazepam, which is a medication used to treat certain types of seizures, panic disorder, and movement disorder. Clonazepam belongs to a class of drugs called benzodiazepines, which work by enhancing the effects of a neurotransmitter in the brain to produce a calming effect. It is usually taken orally as a tablet and is available by prescription only. Clonazepam should be used with caution as it can be habit-forming and has the potential for abuse. Side effects may include drowsiness, dizziness, and difficulty with coordination.

Upstream product

• 1679-18-1 4-Chlorophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 208465-07-0 4-tributylstannanyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 106-39-8 bromochlorobenzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6652-06-8 4-(4-chlorophenyl)-1,2,3,6-tetrahydropiperidine hydrochloride 
• 637-87-6 1-Chloro-4-iodobenzene 
• 15721-22-9 2,2-dimethylvaleroyl chloride 
• 51304-61-1 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 30005-58-4 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine 
• 34619-03-9 tert-butyldicarbonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 873-77-8 (4-chlorphenyl)magnesium bromide 

Downstream Products

• 30005-58-4 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine 
• 725739-49-1 4-(4-chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonyl chloride 
• 475085-48-4 6-(4-chloro-phenyl)-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid tert-butyl ester 
• 946593-11-9 tert-butyl 4-(4-chlorophenyl)piperidine-1-carboxylate 
• 1553930-00-9 2-(2-(4-(4-chlorophenyl)-5,6-dihydropyridin-1(2H)-yl)ethyl)iso-indoline-1,3-dione 
• 917755-88-5 2-(4-(4-chlorophenyl)-5,6-dihydropyridin-1(2H)-yl)ethanamine 
• 1394387-84-8 2-(4-(4-chlorophenyl)-5,6-dihydropyridin-1(2H)-yl)-N-((3-isopropylisoxazol-5-yl)methyl)ethanamine 
• 31776-03-1 4-(4-chloro-phenyl)-3-methyl-piperidin-4-ol 
• 849106-22-5 4-(4-chloro-phenyl)-4-methoxy-3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 849106-23-6 4-(4-chloro-phenyl)-3-hydroxy-4-methoxy-3-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 849106-24-7 4-(4-chloro-phenyl)-4-methoxy-3-methyl-piperidin-3-ol 

Relevant articles and documents

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.